Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company's products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. As of February 26, 2019, the company had operations in 24 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone1-855-279-4652
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$215.10 million
Profitability
Miscellaneous
Employees2,779
Next Earnings Date5/12/2020 (Estimated)
OptionableOptionable
Aurora Cannabis (NYSE:ACB) Frequently Asked Questions
What is Aurora Cannabis' stock symbol?
Aurora Cannabis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ACB."
How were Aurora Cannabis' earnings last quarter?
Aurora Cannabis Inc (NYSE:ACB) posted its earnings results on Thursday, November, 14th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.04. The business had revenue of $57.02 million for the quarter, compared to the consensus estimate of $72.82 million. Aurora Cannabis had a negative net margin of 463.58% and a negative return on equity of 8.22%. View Aurora Cannabis' Earnings History.
When is Aurora Cannabis' next earnings date?
What price target have analysts set for ACB?
17 brokers have issued twelve-month price objectives for Aurora Cannabis' stock. Their forecasts range from $1.00 to $9.07. On average, they expect Aurora Cannabis' stock price to reach $3.33 in the next year. This suggests a possible upside of 96.0% from the stock's current price. View Analyst Price Targets for Aurora Cannabis.
What is the consensus analysts' recommendation for Aurora Cannabis?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurora Cannabis in the last year. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aurora Cannabis.
Has Aurora Cannabis been receiving favorable news coverage?
Media stories about ACB stock have been trending extremely positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aurora Cannabis earned a media sentiment score of 5.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Aurora Cannabis.
Are investors shorting Aurora Cannabis?
Aurora Cannabis saw a increase in short interest in January. As of January 15th, there was short interest totalling 171,210,000 shares, an increase of 9.8% from the December 31st total of 155,950,000 shares. Based on an average daily volume of 27,640,000 shares, the short-interest ratio is currently 6.2 days. Approximately 16.3% of the shares of the company are short sold. View Aurora Cannabis' Current Options Chain.
Who are some of Aurora Cannabis' key competitors?
Some companies that are related to Aurora Cannabis include Canopy Growth (CGC), STADA Arzneimittel (STDAF), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Happiness Biotech Group (HAPP), Sundial Growers (SNDL), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), GLG Life Tech (GLGLF) and True Drinks (TRUU).
What other stocks do shareholders of Aurora Cannabis own?
Who are Aurora Cannabis' key executives?
Aurora Cannabis' management team includes the folowing people:
- Mr. Michael Singer, Exec. Chairman (Age 54)
- Mr. Terry Booth, Founder, CEO & Director (Age 54)
- Mr. Stephen Dobler, Founder, Pres & Director (Age 54)
- Mr. Glen Ibbott, Chief Financial Officer
- Mr. Allan John Cleiren C.A., ICD.D., Chief Operating Officer
Who are Aurora Cannabis' major shareholders?
Aurora Cannabis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include TD Asset Management Inc. (0.26%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Swiss National Bank (0.21%), Renaissance Technologies LLC (0.19%), Think Investments LP (0.17%) and Credit Suisse AG (0.13%).
Which major investors are selling Aurora Cannabis stock?
ACB stock was sold by a variety of institutional investors in the last quarter, including Swiss National Bank, Ladenburg Thalmann Financial Services Inc., TD Asset Management Inc., Renaissance Technologies LLC, Cidel Asset Management Inc., Advisory Services Network LLC, Commerzbank Aktiengesellschaft FI and Mark Sheptoff Financial Planning LLC.
Which major investors are buying Aurora Cannabis stock?
ACB stock was purchased by a variety of institutional investors in the last quarter, including Think Investments LP, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Marshall Wace North America L.P., Credit Suisse AG, SG Americas Securities LLC, Virtu Financial LLC, Oxford Asset Management LLP and Cubist Systematic Strategies LLC.
How do I buy shares of Aurora Cannabis?
Shares of ACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aurora Cannabis' stock price today?
One share of ACB stock can currently be purchased for approximately $1.70.
How big of a company is Aurora Cannabis?
Aurora Cannabis has a market capitalization of $1.99 billion and generates $215.10 million in revenue each year. The company earns $-219,670,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Aurora Cannabis employs 2,779 workers across the globe.View Additional Information About Aurora Cannabis.
What is Aurora Cannabis' official website?
How can I contact Aurora Cannabis?
Aurora Cannabis' mailing address is 10355 JASPER AVENUE SUITE 500, EDMONTON A0, T5J 1Y6. The company can be reached via phone at 1-855-279-4652 or via email at [email protected]
MarketBeat Community Rating for Aurora Cannabis (NYSE ACB)
MarketBeat's community ratings are surveys of what our community members think about Aurora Cannabis and other stocks. Vote "Outperform" if you believe ACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
